Savara (SVRA) EBITDA (2010 - 2026)
Savara (SVRA) reported EBITDA of -$37.6 million for Q1 2026, down 41.87% year-over-year from -$64.7 million in Q1 2025, and down 16.97% quarter-over-quarter from -$32.2 million in Q4 2025.
Savara (SVRA) EBITDA (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of EBITDA data on file, last reported at -$37.6 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$37.6 million, down 41.87% year-over-year; the trailing twelve-month figure through Mar 2026 was -$129.3 million (down 26.66% YoY), and the FY2025 annual result was -$118.2 million, down 22.64% from the prior year.
- EBITDA eased to -$37.6 million in Q1 2026 per SVRA's latest filing, from -$32.2 million in the prior quarter.
- Over five years, EBITDA peaked at -$8.6 million in Q1 2022 and troughed at -$37.6 million in Q1 2026.
- A 5-year average of -$20.3 million and a median of -$20.8 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2024: EBITDA rose 19.78% in 2022, then plunged 99.91% in 2024.
- A 5-year view of EBITDA shows it stood at -$9.3 million in 2022, then tumbled by 65.93% to -$15.4 million in 2023, then plunged by 95.05% to -$30.1 million in 2024, then declined by 6.9% to -$32.2 million in 2025, then decreased by 16.97% to -$37.6 million in 2026.
- Business Quant data shows SVRA's EBITDA at -$37.6 million in Q1 2026, -$32.2 million in Q4 2025, and -$29.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.44 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -65.83 Mn |
| 10 | Savara | 1.33 Bn | 1.33 Bn | - | -37.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.63 Mn |
| Dec 31, 2025 | -32.17 Mn |
| Sep 30, 2025 | -29.50 Mn |
| Jun 30, 2025 | -29.99 Mn |
| Mar 31, 2025 | -26.52 Mn |
| Dec 31, 2024 | -30.09 Mn |
| Sep 30, 2024 | -23.07 Mn |
| Jun 30, 2024 | -22.38 Mn |
| Mar 31, 2024 | -20.82 Mn |
| Dec 31, 2023 | -15.43 Mn |
| Sep 30, 2023 | -16.92 Mn |
| Jun 30, 2023 | -11.60 Mn |
| Mar 31, 2023 | -10.41 Mn |
| Dec 31, 2022 | -9.30 Mn |
| Sep 30, 2022 | -10.98 Mn |
| Jun 30, 2022 | -9.89 Mn |
| Mar 31, 2022 | -8.60 Mn |
| Dec 31, 2021 | -11.59 Mn |
| Sep 30, 2021 | -10.85 Mn |
| Jun 30, 2021 | -10.83 Mn |